Mitsubishi UFJ Trust & Banking Corp Lowers Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mitsubishi UFJ Trust & Banking Corp reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 14.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,161 shares of the medical research company's stock after selling 1,416 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp's holdings in Bio-Rad Laboratories were worth $2,681,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Venturi Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares in the last quarter. Picton Mahoney Asset Management boosted its holdings in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $33,000. UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after acquiring an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at about $38,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

BIO has been the topic of several research analyst reports. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and an average price target of $395.20.

Bio-Rad Laboratories Stock Performance

NYSE BIO traded down $9.54 on Friday, hitting $225.21. 766,924 shares of the company's stock traded hands, compared to its average volume of 300,791. The firm's 50-day moving average price is $281.98 and its two-hundred day moving average price is $319.39. The firm has a market capitalization of $6.31 billion, a PE ratio of -3.46 and a beta of 1.12. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 1-year low of $221.18 and a 1-year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.